Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Ropeginterferon alfa-2b

A modern, individualized approach to managing polycythemia vera
2:30
A modern, individualized approach to managing polycythemia vera
Francesca Palandri • 2 Jul 2026
Ropeginterferon may redefine frontline and second-line treatment in ET
2:26
Ropeginterferon may redefine frontline and second-line treatment in ET
Lucia Masarova • 16 Jun 2026
SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
1:35
SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
Lucia Masarova • 16 Jun 2026
Early versus delayed initiation of ropeginterferon alfa-2b in high-risk ET in the SURPASS-ET trial
2:28
Early versus delayed initiation of ropeginterferon alfa-2b in high-risk ET in the SURPASS-ET trial
Ruben Mesa • 16 Jun 2026
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Yumeng Zhang • 7 Jan 2026
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Mary Frances McMullin • 5 Jan 2026
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 16 Dec 2025
FEDORA preliminary analysis: fedratinib plus ropeginterferon alfa-2b in patients with myelofibrosis
1:49
FEDORA preliminary analysis: fedratinib plus ropeginterferon alfa-2b in patients with myelofibrosis
Adam Mead • 8 Dec 2025
The recent shortage of peginterferon alfa-2a and the role of this agent in MPNs
2:12
The recent shortage of peginterferon alfa-2a and the role of this agent in MPNs
Ruben Mesa • 9 Sep 2025
The most promising emerging therapies and developments in PV and ET
1:56
The most promising emerging therapies and developments in PV and ET
Lucia Masarova • 2 Sep 2025
What's new in essential thrombocythemia in 2025?
1:36
What's new in essential thrombocythemia in 2025?
Alexander Coltoff • 27 Aug 2025
Recent updates and emerging therapies in essential thrombocythemia
1:45
Recent updates and emerging therapies in essential thrombocythemia
Olatoyosi Odenike • 23 Aug 2025
The ECLIPSE-PV trial: comparing two dosing regimens of ropeginterferon alfa-2b in patients with PV
1:30
The ECLIPSE-PV trial: comparing two dosing regimens of ropeginterferon alfa-2b in patients with PV
John Mascarenhas • 23 Aug 2025
Comparing ropeginterferon alfa-2b to anagrelide in ET: topline results of SURPASS-ET
1:21
Comparing ropeginterferon alfa-2b to anagrelide in ET: topline results of SURPASS-ET
Ruben Mesa • 19 Jun 2025
Recent advances and trial updates in MPNs: insights from EHA 2025
7:00
Recent advances and trial updates in MPNs: insights from EHA 2025
Prithviraj Bose • 15 Jun 2025
Topline results from the SURPASS-ET trial: ropeginterferon alfa-2b versus anagrelide in ET
1:52
Topline results from the SURPASS-ET trial: ropeginterferon alfa-2b versus anagrelide in ET
Lucia Masarova • 14 Jun 2025
The content of VJHemOnc is intended for healthcare professionals